{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:15:19Z","timestamp":1767964519235,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00428-018-2393-2","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T20:27:35Z","timestamp":1529526455000},"page":"371-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma"],"prefix":"10.1007","volume":"473","author":[{"given":"Meng-Lei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5051-717X","authenticated-orcid":false,"given":"Navid","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U (2013) Phase II trial (BREAK-2) of the BRAF inhibitor DaBRAFenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 31:3205\u20133211. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.49.8691","journal-title":"J Clin Oncol"},{"key":"2393_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707\u2013714. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112302","journal-title":"N Engl J Med"},{"key":"2393_CR3","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, Bartlett P, Bastian BC, Baylin SB, Behera M, Belyaev D, Benz C, Bernard B, Beroukhim R, Bir N, Black AD, Bodenheimer T, Boice L, Boland GM, Bono R, Bootwalla MS, Bosenberg M, Bowen J, Bowlby R, Bristow CA, Brockway-Lunardi L, Brooks D, Brzezinski J, Bshara W, Buda E, Burns WR, Butterfield YSN, Button M, Calderone T, Cappellini GA, Carter C, Carter SL, Cherney L, Cherniack AD, Chevalier A, Chin L, Cho J, Cho RJ, Choi YL, Chu A, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Coons S, Cope L, Crain D, Curley E, Danilova L, D\u2019Atri S, Davidsen T, Davies MA, Delman KA, Demchok JA, Deng QA, Deribe YL, Dhalla N, Dhir R, DiCara D, Dinikin M, Dubina M, Ebrom JS, Egea S, Eley G, Engel J, Eschbacher JM, Fedosenko KV, Felau I, Fennell T, Ferguson ML, Fisher S, Flaherty KT, Frazer S, Frick J, Fulidou V, Gabriel SB, Gao J, Gardner J, Garraway LA, Gastier-Foster JM, Gaudioso C, Gehlenborg N, Genovese G, Gerken M, Gershenwald JE, Getz G, Gomez-Fernandez C, Gribbin T, Grimsby J, Gross B, Guin R, Gutschner T, Hadjipanayis A, Halaban R, Hanf B, Haussler D, Haydu LE, Hayes DN, Hayward NK, Heiman DI, Herbert L, Herman JG, Hersey P, Hoadley KA, Hodis E, Holt RA, Hoon DSB, Hoppough S, Hoyle AP, Huang FW, Huang M, Huang S, Hutter CM, Ibbs M, Iype L, Jacobsen A, Jakrot V, Janning A, Jeck WR, Jefferys SR, Jensen MA, Jones CD, Jones SJM, Ju Z, Kakavand H, Kang H, Kefford RF, Khuri FR, Kim J, Kirkwood JM, Klode J, Korkut A, Korski K, Krauthammer M, Kucherlapati R, Kwong LN, Kycler W, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lazar AJ, \u0141a\u017aniak R, Lee D, Lee JE, Lee J, Lee K, Lee S, Lee W, Leporowska E, Leraas KM, Li HI, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu O, Liu W, Long GV, Lu Y, Ma S, Ma Y, Mackiewicz A, Mahadeshwar HS, Malke J, Mallery D, Manikhas GM, Mann GJ, Marra MA, Matejka B, Mayo M, Mehrabi S, Meng S, Meyerson M, Mieczkowski PA, Miller JP, Miller ML, Mills GB, Moiseenko F, Moore RA, Morris S, Morrison C, Morton D, Moschos S, Mose LE, Muller FL, Mungall AJ, Murawa D, Murawa P, Murray BA, Nezi L, Ng S, Nicholson D, Noble MS, Osunkoya A, Owonikoko TK, Ozenberger BA, Pagani E, Paklina OV, Pantazi A, Parfenov M, Parfitt J, Park PJ, Park WY, Parker JS, Passarelli F, Penny R, Perou CM, Pihl TD, Potapova O, Prieto VG, Protopopov A, Quinn MJ, Radenbaugh A, Rai K, Ramalingam SS, Raman AT, Ramirez NC, Ramirez R, Rao U, Rathmell WK, Ren X, Reynolds SM, Roach J, Robertson AG, Ross MI, Roszik J, Russo G, Saksena G, Saller C, Samuels Y, Sander C, Sander C, Sandusky G, Santoso N, Saul M, Saw RPM, Schadendorf D, Schein JE, Schultz N, Schumacher SE, Schwallier C, Scolyer RA, Seidman J, Sekhar PC, Sekhon HS, Senbabaoglu Y, Seth S, Shannon KF, Sharpe S, Sharpless NE, Shaw KRM, Shelton C, Shelton T, Shen R, Sheth M, Shi Y, Shiau CJ, Shmulevich I, Sica GL, Simons JV, Sinha R, Sipahimalani P, Sofia HJ, Soloway MG, Song X, Sougnez C, Spillane AJ, Spycha\u0142a A, Stretch JR, Stuart J, Suchorska WM, Sucker A, Sumer SO, Sun Y, Synott M, Tabak B, Tabler TR, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Tatka H, Taylor BS, Teresiak M, Thiessen N, Thompson JF, Thorne L, Thorsson V, Trent JM, Triche TJ Jr, Tsai KY, Tsou P, van den Berg DJ, van Allen EM, Veluvolu U, Verhaak RG, Voet D, Voronina O, Walter V, Walton JS, Wan Y, Wang Y, Wang Z, Waring S, Watson IR, Weinhold N, Weinstein JN, Weisenberger DJ, White P, Wilkerson MD, Wilmott JS, Wise L, Wiznerowicz M, Woodman SE, Wu CJ, Wu CC, Wu J, Wu Y, Xi R, Xu AW, Yang D, Yang L, Yang L, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zhang W, Zhao X, Zhu J, Zhu K, Zimmer L, Zmuda E, Zou L (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u20131696. \n                    https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","journal-title":"Cell"},{"key":"2393_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/jid.2014.366","volume":"135","author":"AE Siroy","year":"2015","unstructured":"Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA (2015) Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135:508\u2013515. \n                    https:\/\/doi.org\/10.1038\/jid.2014.366","journal-title":"J Invest Dermatol"},{"key":"2393_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","volume":"2","author":"KB Dahlman","year":"2012","unstructured":"Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W (2012) BRAF\n                           L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2:791\u2013797. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0097","journal-title":"Cancer Discov"},{"key":"2393_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","volume":"49","author":"O Klein","year":"2013","unstructured":"Klein O, Clements A, Menzies AM, O\u2019Toole S, Kefford RF, Long GV (2013) BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 49:1073\u20131079. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2012.11.004","journal-title":"Eur J Cancer"},{"key":"2393_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CML, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249\u2013256. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70024-X","journal-title":"Lancet Oncol"},{"key":"2393_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","volume":"18","author":"R Dummer","year":"2017","unstructured":"Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, di Giacomo AM, Rutkowski P, del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Boz\u00f3n V, Long GV, Flaherty K (2017) Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:435\u2013445. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30180-8","journal-title":"Lancet Oncol"},{"key":"2393_CR9","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol Off J Am Soc Clin Oncol 24:4340\u20134346. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.06.2984","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2393_CR10","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","volume":"31","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, van den Abbeele AD, Demetri GD, Fisher DE (2013) Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol Off J Am Soc Clin Oncol 31:3182\u20133190. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.47.7836","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2393_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41598-017-00606-w","volume":"7","author":"B Unamuno Bustos de","year":"2017","unstructured":"de Unamuno Bustos B, Murria Estal R, P\u00e9rez Sim\u00f3 G, de Juan Jimenez I, Escutia Mu\u00f1oz B, Rodr\u00edguez Serna M, Alegre de Miquel V, Llavador Ros M, Ballester S\u00e1nchez R, Nagore Engu\u00eddanos E, Palanca Suela S, Botella Estrada R (2017) Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel. Sci Rep 7:495. \n                    https:\/\/doi.org\/10.1038\/s41598-017-00606-w","journal-title":"Sci Rep"},{"issue":"1","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-017-3149-0","volume":"17","author":"A Reiman","year":"2017","unstructured":"Reiman A, Kikuchi H, Scocchia D, Smith P, Tsang YW, Snead D, Cree IA (2017) Validation of an NGS mutation detection panel for melanoma. BMC Cancer 17(1):150. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3149-0","journal-title":"BMC Cancer"},{"issue":"2","key":"2393_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.yexmp.2017.08.006","volume":"103","author":"AP Miraflor","year":"2017","unstructured":"Miraflor AP, de Abreu FB, Peterson JD et al (2017) Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol 103(2):172\u2013177. \n                    https:\/\/doi.org\/10.1016\/j.yexmp.2017.08.006","journal-title":"Exp Mol Pathol"},{"key":"2393_CR14","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2014.6096","volume":"311","author":"RD Carvajal","year":"2014","unstructured":"Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK (2014) Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311:2397\u20132405. \n                    https:\/\/doi.org\/10.1001\/jama.2014.6096","journal-title":"JAMA"},{"key":"2393_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD (2017) Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 101:38\u201344. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034","journal-title":"Br J Ophthalmol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2393-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T19:10:08Z","timestamp":1561057808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2393-2","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"20 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Institutional Review Board of UHCMC, Cleveland, OH. (IRB# 06-16-46C).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}